Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.54. Xtant Medical shares last traded at $0.54, with a volume of 91,934 shares traded.

Xtant Medical Stock Performance

The firm has a 50-day moving average of $0.54. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The stock has a market cap of $75.07 million, a P/E ratio of -4.15 and a beta of 0.35.

Institutional Trading of Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC increased its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 515,006 shares of the medical device company’s stock after buying an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.